trending Market Intelligence /marketintelligence/en/news-insights/trending/37lhMv6zvN1AODrtZAKNsQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Akcea retains rights for heart drug as Novartis opts out of developing therapy

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Akcea retains rights for heart drug as Novartis opts out of developing therapy

Akcea Therapeutics Inc. retained the rights to develop and commercialize heart drug Akcea-APOCIII-LRx after Novartis AG declined to exercise its option to do so.

Boston-based Akcea is developing the therapy for multiple diseases including familial chylomicronemia syndrome, or FCS — a disease which prevents the body from breaking down fats — and cardiovascular disease. The drug works by reducing production of a protein called apoC-III — a process which lowers the levels of triglycerides, a type of fat, and lowers the risk of cardiovascular disease.

Ionis Pharmaceuticals Inc.-unit Akcea, entered into an exclusive, worldwide option and collaboration deal with Switzerland's Novartis in January 2017 to develop and commercialize Akcea-APOCIII-LRx, as well as Akcea-APO(a)-LRx for heart indications.

Ionis and Akcea are evaluating Akcea-APOCIII-LRx in a phase 2 clinical trial to treat patients with hypertriglyceridemia and cardiovascular disease. The companies are expected to release topline results from the trial in early 2020.

In a phase 1/2 clinical study, Akcea-APOCIII-LRx showed significant, dose-dependent reductions in apoC-III protein of up to 84% after six weeks of treatment and a decline in triglyceride levels of up to 71%.